posted on 2021-04-20, 10:59authored byGhulam Ashraf, Mahmoud Ahmed Ebada, Mohd Suhail, Ashraf Ali, Sahab Uddin, Anwar L. Bilgrami, Asma Perveen, Amjad Husain, Mohd Tarique, Abdul Hafeez, Athanasios Alexiou, Ausaf Ahmad, Rajnish Kumar, Naheed Banu, Agnieszka Najda, Amany A. Sayed, Ghadeer M. Albadrani, Mohamed M. Abdel-Daim, Ilaria Peluso, George E. Barreto
The brain is a sexually dimorphic organ that implies different functions and structures depending on sex. Current pharmacological
approaches against different neurological diseases act distinctly in male and female brains. In all neurodegenerative diseases,
including Alzheimer’s disease (AD), sex-related outcomes regarding pathogenesis, prevalence, and response to treatments
indicate that sex differences are important for precise diagnosis and therapeutic strategy. Pathogenesis of AD includes vascular
dementia, and in most cases, this is accompanied by metabolic complications with similar features as those assembled in
diabetes. This review discusses how AD-associated dementia and diabetes affect cognition in relation to sex difference, as both
diseases share similar pathological mechanisms. We highlight potential protective strategies to mitigate amyloid-beta (Aβ)
pathogenesis, emphasizing how these drugs act in the male and female brains.
History
Publication
Oxidative Medicine and Cellular Longevity;article 4572471
Publisher
Hindawi
Note
peer-reviewed
Other Funding information
Deanship of Scientific Research at Princess Nourah bint Abdulrahman University